Regulation of IGF-I mRNA and signal transducers and activators of transcription-3 and -5 (Stat-3 and -5) by GH in C2C12 myoblasts
- PMID: 11796503
- DOI: 10.1210/endo.143.2.8641
Regulation of IGF-I mRNA and signal transducers and activators of transcription-3 and -5 (Stat-3 and -5) by GH in C2C12 myoblasts
Abstract
GH and IGF-I are critical hormones for the regulation of longitudinal growth and the maintenance of lean body mass in humans. The regulation of IGF-I expression by GH in hepatocytes is well documented; however less is known about the regulation of IGF-I in peripheral tissues such as muscle. We have examined the regulation of IGF-I mRNA by GH and IGF-I in C2C12 myoblasts. GH stimulated the accumulation of IGF-I mRNA dose- and time-dependently. An elevation of IGF-I mRNA was observed with GH doses as low as 0.75 ng/ml and after exposure to GH for as little as 1 h, and the increase required ongoing transcription and translation. GH applied in a pulsatile fashion for 10 min followed by an 8-h interpulse interval increased IGF-I mRNA to a greater extent than continuous exposure. GH stimulated tyrosine phosphorylation of the GH receptor, signal transducer and activator of transcription-3 (Stat3), and Stat5. Stat5 was resistant to additional phosphorylation if cells were given a GH pulse within 2 h of a previous GH exposure. The refractory period lasted for 4 h, and cells could be maximally stimulated again after 6 h. Stat3 phosphorylation was also enhanced in cells that were allowed to recover from a previous application of GH. The tyrosine kinase inhibitors, genistein, PP1, and AG-490, and the MAPK kinase inhibitor, PD98059, did not block Stat3 or Stat5 phosphorylation. In contrast, WHI-P154, a Janus kinase-3 inhibitor, dose-dependently prevented Stat3, but not Stat5, phosphorylation. GH-inducible nuclear transport of Stat3 was likewise inhibited by WHI-P154. Most importantly, GH-dependent IGF-I mRNA expression was inhibited by WHI-P154. In contrast, IGF-I mRNA expression was inhibited by IGF-I peptide, and the effect of IGF-I was dominant over that of GH. IGF-I mRNA was regulated by both PI3K and MAPK signal transduction pathways, but IGF-I peptide signaled predominantly through a wortmannin-sensitive pathway to down-regulate its own mRNA. Our data suggest that Janus kinases (Jak2 or Jak3) and their downstream targets (Stat3 and Stat5) may play important roles in the expression of IGF-I mRNA and the myoblast response to GH. In addition, C2C12 cells appear to be a good model system to examine GH regulation of Janus kinase/Stat signaling and the regulation of IGF-I mRNA.
Similar articles
-
GH regulation of IGF-I and suppressor of cytokine signaling gene expression in C2C12 skeletal muscle cells.Endocrinology. 2001 Sep;142(9):3890-900. doi: 10.1210/endo.142.9.8365. Endocrinology. 2001. PMID: 11517167
-
Tumor necrosis factor-alpha decreases insulin-like growth factor-I messenger ribonucleic acid expression in C2C12 myoblasts via a Jun N-terminal kinase pathway.Endocrinology. 2003 May;144(5):1770-9. doi: 10.1210/en.2002-220808. Endocrinology. 2003. PMID: 12697682
-
Desensitization of the growth hormone-induced Janus kinase 2 (Jak 2)/signal transducer and activator of transcription 5 (Stat5)-signaling pathway requires protein synthesis and phospholipase C.Endocrinology. 1998 Apr;139(4):1815-24. doi: 10.1210/endo.139.4.5931. Endocrinology. 1998. PMID: 9528967
-
Cytokine inhibition of JAK-STAT signaling: a new mechanism of growth hormone resistance.Pediatr Nephrol. 2005 Mar;20(3):306-12. doi: 10.1007/s00467-004-1607-9. Epub 2004 Nov 10. Pediatr Nephrol. 2005. PMID: 15549417 Review.
-
Growth hormone signal transduction.J Pediatr Endocrinol Metab. 2002 Jun;15(6):771-86. doi: 10.1515/jpem.2002.15.6.771. J Pediatr Endocrinol Metab. 2002. PMID: 12099386 Review.
Cited by
-
STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancer.Oncotarget. 2017 Sep 12;8(49):85997-86010. doi: 10.18632/oncotarget.20844. eCollection 2017 Oct 17. Oncotarget. 2017. PMID: 29156772 Free PMC article.
-
Carla Task Force on Sarcopenia: propositions for clinical trials.J Nutr Health Aging. 2009 Oct;13(8):700-7. doi: 10.1007/s12603-009-0200-0. J Nutr Health Aging. 2009. PMID: 19657553 Free PMC article.
-
Growth hormone, insulin-like growth factor 1, and insulin signaling-a pharmacological target in body wasting and cachexia.J Cachexia Sarcopenia Muscle. 2011 Dec;2(4):191-200. doi: 10.1007/s13539-011-0043-5. Epub 2011 Oct 20. J Cachexia Sarcopenia Muscle. 2011. PMID: 22207907 Free PMC article.
-
Stimulation of muscle protein synthesis by somatotropin in pigs is independent of the somatotropin-induced increase in circulating insulin.Am J Physiol Endocrinol Metab. 2008 Jul;295(1):E187-94. doi: 10.1152/ajpendo.90253.2008. Epub 2008 May 6. Am J Physiol Endocrinol Metab. 2008. PMID: 18460595 Free PMC article.
-
Mechanism of action of glucagon-like peptide-2 to increase IGF-I mRNA in intestinal subepithelial fibroblasts.Endocrinology. 2011 Feb;152(2):436-46. doi: 10.1210/en.2010-0822. Epub 2010 Dec 15. Endocrinology. 2011. PMID: 21159855 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous